NasdaqGS - Nasdaq Real Time Price USD
Halozyme Therapeutics, Inc. (HALO)
55.08
-0.99
(-1.77%)
As of 10:38:16 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 5 |
| Avg. Estimate | 1.2 | 1.41 | 5.32 | 6.59 |
| Low Estimate | 1 | 1.18 | 4.66 | 4.15 |
| High Estimate | 1.3 | 1.51 | 5.63 | 7.65 |
| Year Ago EPS | 0.91 | 1.27 | 4.23 | 5.32 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 8 | 7 |
| Avg. Estimate | 282.66M | 331.47M | 1.24B | 1.48B |
| Low Estimate | 278M | 325M | 1.2B | 1.22B |
| High Estimate | 288M | 348M | 1.29B | 1.59B |
| Year Ago Sales | 231.35M | 290.08M | 1.02B | 1.24B |
| Sales Growth (year/est) | 22.18% | 14.27% | 22.60% | 18.94% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | 0.76 | 1 | 1.16 | 0.94 |
| EPS Actual | 0.91 | 1.27 | 1.26 | 1.11 |
| Difference | 0.15 | 0.27 | 0.1 | 0.17 |
| Surprise % | 20.10% | 27.05% | 8.73% | 18.55% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 1.2 | 1.41 | 5.32 | 6.59 |
| 7 Days Ago | 1.16 | 1.37 | 5.3 | 6.74 |
| 30 Days Ago | 1.14 | 1.33 | 4.9 | 6.41 |
| 60 Days Ago | 1.15 | 1.34 | 4.93 | 6.45 |
| 90 Days Ago | 1.19 | 1.38 | 5.05 | 6.53 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 2 | 5 | 6 | 4 |
| Down Last 7 Days | 1 | -- | -- | 1 |
| Down Last 30 Days | 1 | 1 | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| HALO | 31.48% | 11.13% | 25.65% | 23.90% |
| S&P 500 | 13.08% | 2.49% | 7.56% | 13.96% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/29/2025 |
| Downgrade | Morgan Stanley: Overweight to Equal-Weight | 5/14/2025 |
| Downgrade | Leerink Partners: Market Perform to Underperform | 5/13/2025 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 5/7/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/25/2025 |
| Maintains | JP Morgan: Neutral to Neutral | 4/21/2025 |
Related Tickers
EXEL Exelixis, Inc.
42.80
-0.56%
CORT Corcept Therapeutics Incorporated
71.91
-7.29%
CPRX Catalyst Pharmaceuticals, Inc.
24.97
+0.02%
ARVN Arvinas, Inc.
7.06
-1.95%
ADMA ADMA Biologics, Inc.
20.05
+1.03%
ACAD ACADIA Pharmaceuticals Inc.
21.33
-1.11%
HRMY Harmony Biosciences Holdings, Inc.
35.17
+1.94%
BBIO BridgeBio Pharma, Inc.
34.42
+0.50%
ARGX argenx SE
573.49
+0.04%
INCY Incyte Corporation
64.94
-0.18%